Received: 9 October 2020
Accepted: 19 October 2020
First Online: 29 October 2020
Change Date: 16 November 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: The Data Protection Officer at Akershus University Hospital (Norway) approved the study. The study (NorPan) was registered in the Covid-19 trial registration at the Norwegian Clinical Research Infrastructure Network. No ethical approval was deemed necessary because no patient data were used.
: Not applicable.
: BWS has received speaking fees from Novartis, unrelated to the present work. ECS has received speaking fees from Bayer and Novartis, unrelated to the present work. JMH has received speaking fees for TEVA and Novartis. AMS, ESK, KWF and SS report no conflicts of interest.